ARVN:NSD-Arvinas, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 63.63

Change

0.00 (0.00)%

Market Cap

USD 3.12B

Volume

0.35M

Average Target Price

USD 111.85 (+75.78%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD65.51B 109.35 N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.66B 20.49 14.38
REGN Regeneron Pharmaceuticals, Inc

N/A

USD52.92B 16.28 12.68
BNTX BioNTech SE

N/A

USD44.37B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD37.67B 55.32 39.57
BGNE BeiGene, Ltd

N/A

USD28.69B N/A N/A
SGEN Seagen Inc

N/A

USD25.31B 38.92 34.59
RPRX Royalty Pharma plc

N/A

USD24.87B 22.60 14.92
GMAB Genmab A/S

N/A

USD24.05B 26.59 3.06
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARVN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.08% 23% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.08% 23% F 11% F
Trailing 12 Months  
Capital Gain 20.56% 55% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.56% 55% F 30% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 45.07% 75% C 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.07% 75% C 85% B
Risk Return Profile  
Volatility (Standard Deviation) 62.78% 49% F 27% F
Risk Adjusted Return 71.80% 91% A- 84% B
Market Capitalization 3.12B 88% B+ 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.90 71% C- 90% A-
Price/Book Ratio 5.12 44% F 33% F
Price / Cash Flow Ratio -34.73 88% B+ 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -33.51% 73% C 29% F
Return on Invested Capital -28.61% 71% C- 24% F
Return on Assets -18.55% 66% D 20% F
Debt to Equity Ratio 0.31% 82% B- 91% A-
Technical Ratios  
Short Ratio 5.22 39% F 23% F
Short Percent 6.02% 56% F 34% F
Beta 2.01 20% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.